Summary & Overview
HCPCS Level II J2326: Injection, nusinersen, 0.1 mg
HCPCS Level II code J2326 designates a 0.1 mg unit of nusinersen, an intrathecal therapy for spinal muscular atrophy. The code is used to bill the drug component of nusinersen administration and is significant nationally because nusinersen is a high-cost, specialty drug with implications for specialty pharmacy, hospital outpatient and infusion billing, and payer coverage policies.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for utilization and cost drivers, an overview of payer coverage approaches and prior authorization patterns, and clinical context about nusinersen dosing and administration settings. The summary highlights reimbursement considerations for hospital outpatient departments and ambulatory infusion centers where intrathecal administration occurs.
The publication provides practical billing context, clarifies the role of J2326 within drug billing lines, and outlines common administrative issues encountered with nusinersen claims. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J2326 represents an injection of nusinersen, measured per 0.1 mg. This code corresponds to the administration of nusinersen, an intrathecal medication used for the treatment of spinal muscular atrophy (SMA).
-
Service type: Drug administration (intrathecal therapy)
-
Typical site of service: Hospital outpatient department or ambulatory infusion center providing intrathecal injections
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or adult with spinal muscular atrophy (SMA) receiving intrathecal administration of nusinersen (J2326, 0.1 mg). The patient presents to an ambulatory infusion center, hospital outpatient department, or specialty clinic for scheduled dosing during the loading or maintenance phase. Pre-procedure steps include verification of diagnosis, review of prior dosing schedule, recent lab tests (platelets, coagulation profile, renal function), and informed consent. The procedure is performed by a neurology or pediatric neurology team with interventional radiology or anesthesia support as needed for difficult lumbar puncture. The patient is positioned for lumbar puncture; sterile technique is used to access the intrathecal space and deliver the medication dose. Post-procedure monitoring includes neurologic observation for cerebrospinal fluid leak, headache, infection signs, and documentation of lot number and dose administered. Billing captures the drug as J2326 per 0.1 mg unit, with appropriate anatomic or service modifiers as indicated, and may be accompanied by CPT codes for professional services such as lumbar puncture or image guidance when performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply to the service |